With supplements/medications for longevity there are a number of considerations. What is your risk profile for the adverse outcome = 100%. However, how modifiable is the risk profile? How much benefit will you actual realize?
I’d suggest that if you are an obese, smoker, with diabetes, Htn, Hyperlipidemia, vascular and kidney disease like so many of my patients - interventions before irreversible disease occurs can likely yield huge benefits.
If, however, you are at IBW, high quality diet, exercising, good muscle base, insulin sensitivity/BP/lipids all good … the same intervention that might yield the earlier individual a 30% life extension might yield you almost nothing as you may already be maximizing or near maximizing pathways the drug(s)/supplements hit.
This has to be paired with side effects. We have a whole lot of items most of us take that yield essentially no adverse effects, for the majority of individuals. This drug would need careful review for a dose and frequency that would be felt to possibly yield rate of aging benefit, while not causing deaths or significant adverse effects. Another issue is unknown risks with longer term use, as generally this drug is utilized for maximum of a year. We don’t know if use for 30 years will yield any manner of unanticipated bad outcomes.
7 Likes
José
#106
FWIW…
We require a “skunk works”
AI-generated answer. Please verify critical facts.
“Testing trametinib serum levels”
Based on the provided information, trametinib serum levels can be quantified using a fully validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The lower level of quantification (LLOQ) of this method is 2 ng/mL.
In clinical trials, trametinib serum concentrations were measured to evaluate the relationships between patient characteristics, adverse events (AE), and exposure. Logistic regression was used to compare the risk of treatment discontinuations or dose reductions with corresponding predicted trough concentrations and area under the curve (AUC) of trametinib.
Key Findings:
- No significant relationships were found between dose reduction or discontinuation due to AE and predicted trametinib serum trough concentrations or AUC.
- The lowest p-values were obtained for trametinib dose reduction or discontinuation vs. predicted trametinib trough concentration (p = 0.08) and predicted trametinib AUC (p = 0.10).
Implications:
- Trametinib serum level testing may not be directly correlated with treatment-related toxicities or dose adjustments.
- Further studies are needed to fully understand the relationships between trametinib exposure and clinical outcomes.
Note: The available information does not provide specific guidance on the optimal range or threshold for trametinib serum levels in clinical practice. Consultation with a healthcare professional and review of relevant clinical guidelines are recommended for accurate interpretation and application of trametinib serum level testing.
AI-generated answer. Please verify critical facts.
Learn more.
1 Like
José
#107
AI-generated answer.
Please verify critical facts
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a powerful analytical technique used for the sensitive and selective detection of trametinib in human serum. This method combines the separating power of liquid chromatography with the highly sensitive and selective mass analysis capability of triple quadrupole mass spectrometry.
Key Features:
Simultaneous determination of trametinib in human serum and plasma
Sensitive and selective detection with limits of quantitation (LOQ) and limits of detection (LOD) not specified
Potential application in daily clinical routine for monitoring trametinib levels
Method Development:
The LC-MS/MS method involves a liquid chromatography separation step, followed by tandem mass spectrometry detection. The chromatographic conditions and mass spectrometric parameters are optimized to achieve high sensitivity and selectivity for trametinib.
Validation:
The method has been validated for its accuracy, precision, and sensitivity. The validation process includes the assessment of matrix effects, ion suppression, and the evaluation of the method’s performance characteristics, such as linearity, recovery, and ruggedness.
Conclusion:**
The LC-MS/MS method for trametinib in serum is a reliable and sensitive analytical technique for the detection and quantitation of this kinase inhibitor in human serum. Its application in clinical settings can facilitate the monitoring of trametinib levels and support personalized medicine approaches.
AI-generated answer.
Please verify critical facts
How does this differ from datasatnib which is already in common use as a Q 2 week for 2 day treatment in combination with rapamycin.
1 Like
While their names are somewhat similar, they are very different compounds used in very different applications (and while dasatinib has been identified as a senolytic, trametinib has not).
4 Likes
Sample of pricing on the 0.5 mg tablets, from India.
Trametinib 0.5mg - 30 tablets - 665$ US
Or about $22 per 0.5mg tablet
US Prices:
Or about $163 per 0.5mg tablet.
Source: Mekinist Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
1 Like
Ludovic
#111
Prices here in Europe are better then in the US, but it’s still a very expensive drug;
1340,96 euros (30 x 0,5 mg).
5109,37 euros (30 x 2 mg).
Unfortunately I don’t want to take the risk of trying to import from India, because an order of Dasatinib from India was confiscated by customs 2 years ago, so this means shipping to my adress gets extra checked and when I try to import medication from abroad again, I will get prosecuted…
1 Like
We can order these drugs in the US. The question is how would we dose the senolytic if it were once every 2 weeks like Datasatnib. Someone suggested 7 mg would be the human dosing equivalent for 60kg man from the study where they gave 2mg daily to the animals.
It would be very hard to get a prescription for this in the USA (its a drug for cancer), and it needs to be refrigerated, so hard to order from India without it being spoiled.
The dosing I calculated where I suggested 7mg was the dosing, was based on a mistake I made at interpreting the 1.44mg/kg as a dose as a function of the weight of the animal. It is actually a dose calculated as a percent of the weight of the food given to the animals - so skip that calculation. It seems the dose we should likely try for humans is in the range of 0.125mg per week, to 0.5mg once every 20 days or so. Since you can’t pill split with this medication (they are coated in a film, we seem to have to use 0.5mg dosing unless there is a way to get the liquid formulation. We need to carefully track to see if there are the same negative effects that are seen at higher dosing.
1 Like
Neo
#114
@RapAdmin i saw @cl-user say that the pills can be split IF combined with enteric capsules
Just wanted to see if you missed that or if you don’t agree with it being an option that could work
My concern around that approach is that we don’t know which enteric capsule is going to replicate the effect of the film coating of the tablets and there is no commercially available blood level test we can use to validate efficacy.
Maybe I am overthinking it, but I would like some way to validate that the capsule approach is working.
It seems to me that the only way we can really be sure that the drug is getting into the bloodstream is if you use the 0.5mg tablet.
1 Like
tananth
#116
The type of coating used could be an enteric coating (to protect from stomach acid) OR could be coating to mask the terrible taste of Trametinib. Given that Trametinib is available in a liquid solution, this suggests that enteric coating is not the function, though I suppose the liquid version could be loaded with acid-buffer.
Both the tablet version and liquid version of Trametinib is supposed to be taken on an empty stomach, suggesting that long term exposure to stomach acid is to be avoided.
cl-user’s suggestion of using enteric coated capsules should cover the bases either way, unless I am missing something.
1 Like
J0hn
#117
Another possibility is the film on the tablet is there to protect the Trametinib dimetyl sulphoxide from contact with the atmosphere. DMSO is a (admittedly very low) volatile solvent. Loss of DMSO I would imagine, would seriously screw with drug bioavailability.
…curiously, the Trametinib solution is supplied as a powder ready for reconstitution.
2 Likes
José
#118
FWIW…
DMSO would increase the bioavailability of this and most compound’s.
If you search this forum you will find a link/posting of a PDF copy of the medical book {this is a real medical book not a consumer book] on DMSO, titled;
“Dimethyl Sulfoxide (DMSO) in Trauma and Disease”
By Stanley W. Jacob MD and Jack C. de la Torre
If you know how to use DMSO you can deliver just about any compound systemically.
Why change?
You can purchase the “approved drug” for Quantity Per unit Price for
30 X .05mg at $163.43 each for $4,902.77 as of 08/13/2024
You can make it yourself with better bioavailability for less than $150.00 for 200 x .5mg doses
2 Likes
If someone has the time to dig deep and find out exactly why the the tablets have a film coating that would be really helpful. I have searched but not found anything yet.
I asked Dr. Oracle
The film on trametinib dimethyl sulphoxide tablets serves a critical purpose in maintaining the stability and efficacy of the medication. Its primary function is to:
Protect the tablet from moisture exposure
Preserve the dimethyl sulfoxide (DMSO) content of the tablet
Bioavailability Preservation
DMSO content is crucial for maintaining trametinib bioavailability
Loss of DMSO can adversely impact the drug’s effectiveness ([1])
4 Likes
Great info! Can you ask Dr. Oracle how they get around this issue with the liquid formulation of trametinib?
1 Like
jnorm
#122
Storage in an amber glass vial should work fine. [ref]
Now you guys have me digging through enteric coating patents to learn how to coat my own tablets.
*Not medical advice. Consult a compounding pharmacist and patent lawyer. 
1 Like
José
#124
“Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long‐Term Storage at Room Temperature”
This study was sponsored and funded by Novartis Pharmaceuticals Corporation.
4 Likes
